Epidarex Capital

Epidarex Capital is an early-stage venture firm based in Edinburgh that identifies and builds breakthrough life science companies in emerging academic hubs outside traditional mega-clusters. The firm explicitly targets biotech, pharma/therapeutics, and life sciences tools opportunities arising from UK and US universities and research institutions located outside Boston, the Bay Area, and London proper, on the thesis that great science is increasingly distributed and undercapitalized in those regions. Their model often involves company creation alongside founding scientists rather than passive investment.

Epidarex invests at Seed and Series A with checks of $1M to $5M, frequently leading or co-leading rounds and taking active board roles. Geographic focus spans the UK, particularly Scotland and the wider regional university base, alongside select US emerging hubs.

Founders should expect a partner who engages deeply on company formation, IP strategy, scientific advisory composition, and downstream syndication. Approach with a clear scientific thesis, defensible IP position, and willingness to operate in close collaboration on team build-out. Warm introductions through university tech transfer offices or existing portfolio scientists carry significant weight.